Dr. Oregonin, a bio-company located in Chuncheon and led by CEO Choi Seon-eun, has successfully achieved technology commercialization and investment attraction with the support of Gangwon TP, becoming a noteworthy regional success story. Dr. Oregonin, a university spin-off company, initially faced difficulties after being selected for the TIPS program, such as challenges in clearly explaining the marketability and commercialization potential of its technology to investors and a lack of experimental data and technical validation in existing markets.

To address these issues, Gangwon TP provided support, including the establishment of revenue generation models for domestic and international markets to attract large-scale investments, proof-of-concept (PoC) studies to validate technical feasibility, enhancement of existing IR materials with objective data, assistance in entering overseas markets through international exhibitions, and participation in investment events such as Gangwon Investment Partners Day and the Commercialization Technology + Investment Presentation. Through these efforts, Dr. Oregonin improved its IR materials using PoC validation, developed revenue models through international market entry, and created a roadmap to increase the success rate of commercialization by connecting with investors.

As a result, Dr. Oregonin successfully verified the pre-commercialization potential of its technology through research conducted by the Daegu-Gyeongbuk Advanced Medical Industry Promotion Foundation, focusing on the effects of native arboreal resources on oxidative stress and cardiotoxicity. This achievement led to the signing of seven technology transfer agreements worth KRW 100 million. Additionally, with support from Chuncheon City’s overseas marketing program, Dr. Oregonin participated in international exhibitions in Vietnam, Malaysia, and Japan, resulting in its first export supply agreement worth USD 1.6 million. Currently, the company is expanding its product and technology exports to the United States and Southeast Asia.

Subsequently, at events hosted by Gangwon TP, including Gangwon Investment Partners Day and the Commercialization Technology + Investment Presentation, Dr. Oregonin was recognized for its business potential and successfully secured KRW 1.8 billion in follow-up investments, including funding from Sopoong Ventures, a Gangwon-based venture capital firm.

This success is attributed to Dr. Oregonin’s outstanding technological capabilities and Gangwon TP’s systematic support and investment strategy. As a result of these accomplishments, Dr. Oregonin received the Minister of SMEs and Startups Award, becoming a benchmark case for promoting the growth of small and medium-sized enterprises and venture businesses. This success story highlights the potential of Gangwon’s innovative ecosystem to maximize corporate competitiveness through technology commercialization.

Director Heo Jang-hyun of Gangwon TP stated, “In a time when venture investments are declining and tech-transfer companies face difficulties in securing funding, regional support and investment are more critical than ever. We will continue to strengthen investment linkages for tech-transfer companies and advance our support system for commercialization, helping local businesses overcome challenges and achieve sustainable growth.”